Real-world comparison of short-term adverse events, treatment persistence, and efficacy of semaglutide and tirzepatide: A nationwide multicenter study

Basit Öğe Kaydı
dc.authorid0000-0002-8375-7409
dc.authorid0000-0002-6866-2364
dc.authorid0000-0003-0577-0533
dc.authorid0000-0001-9850-0481
dc.authorid0000-0001-8433-4769
dc.authorid0000-0001-9806-3891
dc.authorid0000-0001-6492-3064
dc.authorid0000-0003-4867-3725
dc.authorid0000-0002-9309-7715
dc.contributor.authorHepşen, Sema
dc.contributor.authorHaymana, Cem
dc.contributor.authorErtepe Küçükgöde, Gizem
dc.contributor.authorÖzcan, Büşra
dc.contributor.authorÖzbaş, Burak
dc.contributor.authorOr Koca, Arzu
dc.contributor.authorAydoğan, Berna İmge
dc.contributor.authorTura Bahadır, Çiğdem
dc.contributor.authorSalman, Serpil
dc.contributor.authorSönmez, Alper
dc.date.accessioned2026-04-30T13:18:07Z
dc.date.available2026-04-30T13:18:07Z
dc.date.issued2026
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, treatment discontinuation, body weight loss (BWL), and metabolic outcomes between the two treatments. Methods: This study included 2,549 patients with obesity treated with semaglutide (n=1,434) or tirzepatide (n=1,115). Adverse events, including time to onset, dose at occurrence, and related discontinuation, were evaluated. Changes in BWL and metabolic parameters up to 6 months were assessed. Subgroup analyses were performed in patients with and without type 2 diabetes mellitus (T2DM). Results: At least one adverse event occurred in 50.9% in the semaglutide group and 51.0% in the tirzepatide group (p=0.524), with gastrointestinal events the most frequently reported. Overall adverse event rates were comparable between groups; however, musculoskeletal and allergic reactions were more common in the tirzepatide group. The onset of gastrointestinal, neuropsychiatric, musculoskeletal symptoms, and hypoglycemia occurred earlier in the tirzepatide group. Discontinuation due to adverse events was similar between groups, except for pancreatic events, which were more frequent in the semaglutide group (p=0.006). Tirzepatide was associated with greater early BWL at all time points. At 6 months, median percentage BWL was 12.6% with semaglutide and 14.4% with tirzepatide. HbA1c reductions were comparable between groups in patients with T2DM. Conclusion: In real-world clinical practice, semaglutide and tirzepatide show similar short-term tolerability and treatment persistence, although tirzepatide is associated with a higher incidence of musculoskeletal and allergic reactions and greater early BWL.
dc.identifier.citationHepşen, S., Haymana, C., Ertepe Küçükgöde, G., Özcan, B., Özbaş, B., Or Koca, A., Aydoğan, B. İ., Tura Bahadır, Ç., Salman, S., & Sönmez, A. (2026). Real-world comparison of short-term adverse events, treatment persistence, and efficacy of semaglutide and tirzepatide: A nationwide multicenter study. Obesity Facts, pp. 1-23. https://doi.org/10.1159/000552104
dc.identifier.doi10.1159/000552104
dc.identifier.endpage23
dc.identifier.issn1662-4025
dc.identifier.issn1662-4033
dc.identifier.pmidPMID: 42030208
dc.identifier.scopusqualityQ1
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.1159/000552104
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1462
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorSalman, Serpil
dc.institutionauthorid0000-0003-4867-3725
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofObesity Facts
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdverse Events
dc.subjectEfficacy
dc.subjectSafety
dc.subjectSemaglutide
dc.subjectTirzepatide
dc.subjectTreatment Persistence
dc.titleReal-world comparison of short-term adverse events, treatment persistence, and efficacy of semaglutide and tirzepatide: A nationwide multicenter study
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Tam Metin / Full Text.pdf
Boyut:
2.84 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu